NY marks $38M for breast cancer screening initiative

Gov. Andrew Cuomo of New York announced that $37.7 million in funding has been...Read more on AuntMinnie.comRelated Reading: What are the risks of risk-based breast cancer screening? USPSTF's breast cancer screening recs dampen compliance Most women prefer annual breast cancer screening ACR releases breast cancer screening criteria NY governor signs breast cancer screening access bill
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Three-dimensional mammography screening detected 34 percent more breast cancer tumors than the traditional process of a single image, according to a study.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Conclusion: Certain MRI features of TNBC such as heterogeneous or rim enhancement, intratumoral very high signal intensity on T2 images, and peritumoral edema might be useful in predicting the prognosis of patients with TNBC.Oncol Res Treat
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 October 2018Source: Journal of Geriatric OncologyAuthor(s): Gabor Liposits, Kah Poh Loh, Enrique Soto-Perez-de-Celis, Lucy Dumas, Nicolò Matteo Luca Battisti, Sindhuja Kadambi, Capucine Baldini, Susana Banerjee, Stuart M. LichtmanAbstractBreast and ovarian cancer are common malignancies among older adults, causing significant morbidity and mortality. Although most cases of breast and ovarian cancer are sporadic, a significant proportion is caused by mutations in cancer susceptibility genes, most often breast cancer susceptibility genes (BRCA) 1 and 2. Furthermore, some breast an...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThe G8 screening tool has a potential role in predicting side effects during a treatment with aromatase inhibitor. G8 could be very useful in everyday clinical practice for this population.
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractBackgroundDetection of breast cancers by mammographic screening confers a survival advantage of 20 –50% compared to symptomatic presentations. The improved prognosis is only partly explained by stage migration. The distribution of the molecular subtypes of screen-detected breast cancer (SDBC) or their HER2 status has not been studied extensively. We wished to address these issues through the st udy of a large series of SDBC, with other presentations serving as controls.DesignDeidentified cases of female invasive cancer, diagnosed in Australia and New Zealand during 2005 –2015, were retrieved from the Br...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
We examined trends in RT use over 10  years, and the impact of sociodemographic factors on the receipt of standard-of-care RT, using the National Cancer Database (NCDB).Materials/methodsWomen under age 70 with invasive breast cancer who underwent BCS from 2004 to 2014 were analyzed. Receipt of RT was evaluated in the whole cohort and by time period to identify temporal trends. Multiple logistic regression models were used to assess associations between factors such as race, insurance status, ethnicity, and receipt of RT.ResultsA total of 501,733 patients met eligibility criteria. The percentage of patients undergoing ...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeBRCA1 andBRCA2 genotyping results have clinical implications for cancer risk assessment and targeted therapy. Current practice in Israel is to genotype for the predominantBRCA1/2 mutations first, followed by full gene analysis in eligible mutation-negative individuals. This work assessed the rate of non-predominant mutations inBRCA1/2 in ethnically diverse high-risk cases.MethodsBreast and/or ovarian cancer patients who tested negative for the predominantBRCA1/2 mutations were referred for comprehensiveBRCA1/2 genotyping if calculated risk for carrying aBRCA mutation was ≥ 10%.ResultsOf 1258 eligible...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Funding | Women